** Shares of Neuren Pharmaceuticals NEU.AX rise 11% to A$13.92, their highest since June 13
** Stock is the top gainer on the benchmark index .AXJO
** Stock on track for best day since April 14 if gains hold
** Co receives patent application approval from U.S. regulator for the use of its NNZ-2591 drug to treat Pitt Hopkins syndrome, a neurodevelopmental condition
** Says patent's expiry date will be in April 2040
** Including day's moves, stock up 11.7% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。